FDA says no indication contaminated cough syrups have entered U.S.
supply chain
Send a link to a friend
[March 04, 2023]
(Reuters) - The U.S. Food and Drug Administration (FDA) said on
Friday there was no indication that contaminated cough and paracetamol
syrups that caused deaths of children in Gambia last year have entered
the U.S. drug supply chain.
This comes after an investigation led by the U.S. Center for Disease
Control and Prevention and Gambian scientists reported on Thursday that
these medicines contaminated with toxic levels of diethylene and
ethylene glycol led to acute kidney injury among 78 children in Gambia.
"We will continue to monitor the situation and keep the public and
health care professionals updated of any changes in status to the U.S.
market," Patrizia Cavazzoni, director for FDA's Center for Drug
Evaluation and Research, said in a tweet.
[to top of second column]
|
![](../images/030423PIX/health51.jpg)
Signage is seen outside of the Food and
Drug Administration (FDA) headquarters in White Oak, Maryland, U.S.,
August 29, 2020. REUTERS/Andrew Kelly/File Photo
![](http://archives.lincolndailynews.com/2023/Mar/04/images/ads/current/friendshipmanor_sda_BASKETBALL_2022.png) In October, the World Health
Organization sent out an alert saying four cough syrups containing
toxic levels of diethylene and ethylene glycol made by India's
Maiden Pharmaceuticals Ltd should be withdrawn.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |